🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
129 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study
2024-519884-16-00Sjögren's syndrome
Radboud universitair medisch centrum Stichting
Immune System Diseases
Netherlands
11/03/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
2025-522831-33-00Hidradenitis Suppurativa
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
France, Poland, Netherlands, Germany
06/03/2026
Phase II
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis
2025-522511-42-00Crohn's disease, Colitis Ulcerative
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase II
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study
2025-522060-32-00STEMI (ST elevated Myocardial Infarction)
CorFlow Therapeutics AG, CorFlow Therapeutics AG
Cardiovascular Diseases
Netherlands, Spain, France
02/03/2026
Phase II
Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
2025-522834-30-01Systemic sclerosis (SSc), Idiopathic pulmonary fibrosis (IP…
Amsterdam UMC Stichting
Skin and Connective Tissue Diseases
Netherlands
02/03/2026
Phase II
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Italy, Poland, Spain, Finland, Netherlands, Greece
24/02/2026
Phase II
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium
18/02/2026
Phase II
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00Acute Myeloid Leukemia
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the effects of SUL-238 on High Energy Phosphates with Magnetic Resonance Spectroscopy (31P-MRS) in patients with Early, untreated Parkinson’s Disease (“SHEPHERD” STUDY)
2025-524674-42-00Parkinson’s Disease
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.
Nervous System Diseases
Netherlands
13/02/2026
Phase II
Accuracy for Imaging Cardiac Sarcoidosis with 68Ga-Pentixafor Positron Emission Tomography/Computed Tomography (68Ga-Pentixafor PET/CT): ASPECT study
2025-523646-27-00Cardiac Sarcoidosis
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Diagnosis
Netherlands
12/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.
2025-523231-19-00Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.
Neoplasms
Italy, Germany, Greece, Spain, Austria, France, Netherlands
10/02/2026
Phase II
Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study
2025-523032-39-00Non-small cell lung cancer
Academisch Ziekenhuis Maastricht
Diagnosis
Netherlands
03/02/2026
Phase II
ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial
2023-504404-28-00Chronic Kidney Disease, Type 1 Diabetes
University Medical Center Groningen
Nutritional and Metabolic Diseases
Netherlands, Finland, Denmark
02/02/2026
Phase II
J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00Asthma
Eli Lilly & Co.
Respiratory Tract Diseases
Germany, Netherlands, France, Poland
21/01/2026
Phase II
Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson’s Disease
2025-521819-39-00Parkinson's disease
Amsterdam UMC Stichting
Nervous System Diseases
Netherlands
05/01/2026
Phase II
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa
2025-522333-61-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece
22/12/2025
Phase II
A single-center, randomized, double blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
2025-522922-11-00Progressive multiple sclerosis (MS)
Idorsia Pharmaceuticals Ltd.
Nervous System Diseases
Netherlands
08/12/2025
Phase II
SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial
2025-521866-92-01long COVID
Amsterdam UMC Stichting
Virus Diseases
Netherlands
02/12/2025
Phase II
A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
2025-522146-40-00Late-onset Pompe disease.
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase II
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Inc.
Genetic Phenomena
France, Germany, Italy, Belgium, Spain, Netherlands
28/11/2025
Phase II
BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED.
2023-508116-32-00Antibody-mediated rejection of renal grafts, High HLA-immun…
Academisch Ziekenhuis Leiden
Immune System Phenomena
Netherlands
27/11/2025
Phase II
A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative
2023-506982-73-00high risk or poor response after chemoradiation and brachyt…
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Female Urogenital Diseases and Pregnancy Complications
Netherlands
25/11/2025
Phase II
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy
Imbria Pharmaceuticals Inc.
Cardiovascular Diseases
Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland
20/11/2025
Phase II
A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation
2025-520518-79-00Atrial Fibrillation
Novartis Pharma AG
Cardiovascular Diseases
Netherlands, Germany
17/11/2025
Phase II
A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization
2025-521325-33-00Chronic angina and left ventricular dysfunction due to coro…
Xylocor Therapeutics Inc.
Cardiovascular Diseases
Netherlands, Germany, Hungary, Poland
11/11/2025
Rows per page Showing 76–100 of 129
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.